A plasma-stable analgesic peptide
By linking the α-conotoxin of the α9α10 acetylcholine receptor with fatty acids and polyethylene glycol to form a conjugate, the problem of poor stability of the peptide in the organism is solved, and higher plasma stability and analgesic activity are achieved. More feasible drug development programs are provided.
Patent Information
- Application Number
- CN202211006154.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-08-22
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2042-08-22
AI Technical Summary
Existing analgesic polypeptide drugs have poor stability in organisms and are easily degraded by proteases, resulting in high blood and kidney clearance rates, limiting their practical applications.
By linking the α-conotoxin and its derivatives of the α9α10 acetylcholine receptor with fatty acids and polyethylene glycol through covalent amide or ester bonds, it forms a conjugate, preventing the degradation of the polypeptide by proteases in plasma and improving its Plasma stability.
It significantly improves the plasma stability of the peptide, prolongs its half-life in the body, enhances its analgesic activity, and reduces cytotoxicity, providing a more feasible drug development plan.
Smart Images

Figure BDA0003808776480000031 
Figure BDA0003808776480000041 
Figure BDA0003808776480000042
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and specifically to a polypeptide with analgesic activity, and particularly to an analgesic active polypeptide with plasma stability. Background Art
[0002] Neuropathic pain is a chronic pain caused by damage to the peripheral or central nervous system, which afflicts 8% of the world's population. It not only seriously affects the patient's physical and mental health and quality of life, but also consumes tens of billions of dollars in medical resources (NB Finnerup, R. Kuner, and TS Jensen, "Neuropathic Pain: From Mechanisms to Treatment." Physiol Rev, vol. 101, no. 1, pp. 259–301, Jan. 2021). The number of patients with neuropathic pain in my country far exceeds 100 million, and the medical losses caused by neuropathic pain are greater than the sum of the three major diseases of cancer, heart disease and diabetes, but no targeted drug for the treatment of neuropathic pain has yet been found (Chang Sun Dongting, Luo Sulan. Preclinical study of the new analgesic marine drug conotoxin GeXIVA [C]. Proceedings of the 14th Biotoxin Toxicology Conference and the 1st Biotoxin-From Survival Adaptation to Translational Medicine Special Academic Conference. 2019: 31.).
[0003] At present, opioids and nonsteroidal anti-inflammatory drugs are the most commonly used analgesics in clinical practice, but these drugs have many side effects, such as drowsiness, nausea, respiratory depression, vomiting, constipation and gastrointestinal disorders. In particular, opioids have a clear tendency to be abused (SB Christensen et al., "RgIA4 Potently Blocks Mouse α9α10nAChRs and Provides Long Lasting Protection against Oxaliplatin-Induced Cold Allodynia," Frontiers in Cellular Neuroscience, vol. 11, 2017). In addition to opioid receptors, other analgesic targets such as acetylcholine receptors, sodium ion channels, and calcium ion channels have gradually attracted the attention of researchers. Studies have shown that the α9α10 subtype of acetylcholine receptors may be potential targets for the treatment of chronic pain, especially neuropathic pain (Zhu Deyuan, Wang Yiran, Cai Guojun, Xu Tianying. Research progress on nicotinic acetylcholine receptors as analgesic targets [J]. Journal of Pharmaceutical Practice, 2015, 33(04): 309-312+375.).Antagonists of α9α10 acetylcholine receptor (nAChR) have shown good analgesic effects in animal pain models. Among them, α-conotoxin Vc1.1, RgIA and GeXIVA are currently the most active mouse α9α10 nAChR inhibitors. All three have shown excellent analgesic effects in different animal pain models (DW Sandall et al., "A Novel α-Conotoxin Identified by Gene Sequencing Is Active in Suppressing the Vascular Response to Selective Stimulation of Sensory Nerves in Vivo," Biochemistry, vol. 42, no. 22, pp. 6904–6911, Jun. 2003; M. Ellison et al., "α-RgIA: A Novel Conotoxin That Specifically and Potently Blocks theα9α10nAChR," Biochemistry, vol.45, no.5, pp.1511–1517, Feb.2006; Luo Sulan et al., "Cloning, synthesis, and characterization of αO-conotoxin GeXIVA, a potentα9α10nicotinicacetylcholine antagonist receptor," Proceedings of the National Academy ofSciences, vol.112, no.30, pp.E4026–E4035, Jul.2015). However, the activity of Vc1.1 and RgIA on rodent α9α10 nAChR is much higher than that on human α9α10 nAChR, leading to the termination of the study (Bufalo DelAlessandra, Cesario Alfredo, Salinaro Gianluca, Fini Massimo and Russo Patrizia, Alpha9Alpha10 Nicotinic Acetylcholine Receptors as Target for the Treatment of Chronic Pain, Current Pharmaceutical Design. 20(38)2014.).
[0004] Conotoxin (GeXIVA) is a marine-derived bioactive peptide, usually composed of 10-50 amino acid residues, rich in secondary structures and several disulfide bonds. Its stable structure and diverse pharmacological effects have shown it a very broad prospect in drug development. Conotoxins are divided into different gene families according to the similarity of the endoplasmic reticulum signal peptide sequence and cysteine pattern of their precursor proteins. To date, all known conotoxins can be divided into 18 superfamilies; conotoxins (peptides) can be divided into multiple pharmacological families such as α, ω, μ, and δ according to their receptor targets. Among them, α-conotoxins have the function of blocking nicotinic acetylcholine receptors (nAChRs); conotoxin peptides that do not contain cysteine have the function of blocking N-methyl-D-aspartate receptors (NMDA receptor, N-methyl-D-aspartic acid receptor, NMDAR) (Ai-Hua Jin, Markus Muttenthaler, Sebastien Dutertre, SWAHimaya, Conotoxins: Chemistry and Biology,” Chem. Rev., vol. 119, no. 21, pp. 11510–11549, Nov. 2019). Among them, α-conotoxins RgIA, Vc1.1 and GeXIVA, which selectively inhibit α9α10 acetylcholine receptors, showed good analgesic effects in animal pain models, and can relieve pain caused by trauma, inflammation or nerve damage through subcutaneous or intramuscular injection. The discovery of GeXIVA avoids the disadvantage of large species differences, but its long sequence and complex structure also make it face thorny problems in drug development. By simplifying and modifying the structures of GeXXVIIA and GeXIVA in conotoxins, a series of linear polypeptide compounds with comparable activity to GeXIVA and simple structure were obtained, such as Gex-2, etc. Although these modified linear polypeptide compounds have good analgesic effects, they also have the common disadvantages of polypeptide drugs: they are easily degraded by a variety of proteases, and have high blood and kidney clearance rates, resulting in poor in vivo stability and many limitations in practical applications. Summary of the invention
[0005] Improving the stability of peptides in the body is the key to developing peptide drugs. Reducing the degradation of peptide derivatives by proteases provides a direction for solving the above technical problems.
[0006] Therefore, in a first aspect, the present invention provides an analgesic polypeptide, wherein the structure of the polypeptide is AB.
[0007] Wherein A represents α-conotoxin of α9α10 acetylcholine receptor and its modified polypeptide derivatives, such as PeIA and its derivatives, RgIA and its derivatives RgIA4, Vc1.1 and its derivatives, GeXIVA and its derivatives, Gex-2 and its analogs, etc.
[0008] Wherein B represents a conjugate, and the conjugate can prevent proteases in plasma from degrading α-conotoxin and modified polypeptide derivatives of α-conotoxin.
[0009] Further, the conjugate is selected from fatty acids and polyethylene glycol, and further, the carbon number of the fatty acid is C 2-25 , preferably C 2-20 , more preferably the number of carbon atoms is C 10-20 , further preferably the fatty acid chain in Table 1; the molecular weight of the polyethylene glycol is not less than 1000, preferably 300-800, and further preferably the polyethylene glycol (PEG) in Table 2.
[0010] A and B are linked by a covalent bond, which is an amide bond or an ester bond.
[0011] Table 1:
[0012]
[0013]
[0014] Table 2
[0015]
[0016]
[0017] In a second aspect, the present invention provides an analgesic pharmaceutical composition, which contains an analgesic polypeptide having a structure of AB according to the present invention and optional pharmaceutically acceptable excipients, wherein A represents α-conotoxin of α9α10 acetylcholine receptor and its modified polypeptide derivatives, such as PeIA and its derivatives, RgIA and its derivatives RgIA4, Vc1.1 and its derivatives, GeXIVA and its derivatives, Gex-2 and its analogs, etc.
[0018] Wherein B represents a conjugate, and the conjugate can prevent proteases in plasma from degrading α-conotoxin and modified polypeptide derivatives of α-conotoxin.
[0019] Further, the conjugate is selected from fatty acids and polyethylene glycol, and further, the carbon number of the fatty acid is C 2-25 , preferably C 2-20, more preferably the number of carbon atoms is C 10-20 , further preferably the fatty acid chain in Table 1; the molecular weight of the polyethylene glycol is not less than 1000, preferably 300-800, and further preferably the polyethylene glycol (PEG) in Table 2.
[0020] A and B are linked by a covalent bond, which is an amide bond or an ester bond.
[0021] In a third aspect, the present invention provides the use of analgesic polypeptides having a structure of AB according to the present invention in drugs for treating pain diseases, wherein A represents α-conotoxin of α9α10 acetylcholine receptor and its modified polypeptide derivatives, such as PeIA and its derivatives, RgIA and its derivatives RgIA4, Vc1.1 and its derivatives, GeXIVA and its derivatives, Gex-2 and its analogs, etc.
[0022] Wherein B represents a conjugate, and the conjugate can prevent proteases in plasma from degrading α-conotoxin and modified polypeptide derivatives of α-conotoxin.
[0023] Further, the conjugate is selected from fatty acids and polyethylene glycol, and further, the carbon number of the fatty acid is C 2-25 , preferably C 2-20 , more preferably the number of carbon atoms is C 10-20 , further preferably the fatty acid chain in Table 1; the molecular weight of the polyethylene glycol is not less than 1000, preferably 300-800, and further preferably the polyethylene glycol (PEG) in Table 2.
[0024] A and B are linked by a covalent bond, which is an amide bond or an ester bond.
[0025] The pain categories include neuralgia, addiction, Parkinson's disease, epilepsy, local ischemia, excitatory neuronal cell death, dementia, breast cancer, lung cancer, encephalomyelitis, cancer and cancer chemotherapy, alcoholism, sciatica, diabetes, trigeminal neuralgia, sclerosis, herpes zoster, mechanical and surgical injuries, AIDS, head nerve paralysis, drug poisoning, industrial pollution poisoning, lymphatic neuralgia, myeloma, multi-point motor neuropathy, chronic congenital sensory neuropathy, acute severe spontaneous neuralgia, compression neuralgia, vasculitis, vasculitis, local ischemia, uremia, childhood biliary liver disease, chronic respiratory disorders, complex neuralgia, multiple organ failure, sepsis / sepsis, hepatitis, porphyria, vitamin deficiency, chronic liver disease, primary biliary sclerosis, hyperlipidemia, leprosy, Lyme arthritis, sensory perineuritis or allergy.
[0026] In a fourth aspect, the present invention further provides a method for preparing an analgesic polypeptide having a structure of AB, the method comprising the following steps:
[0027] 1) Solid phase synthesis of linear polypeptides (A):
[0028] 2) A and the conjugate are reacted with a condensing agent at room temperature to complete condensation, and further purified by reverse HPLC.
[0029] The condensing agent is selected from 2 eq of Pybop (benzotriazole-1-yl-oxytripyrrolidinophosphine hexafluorophosphate) and 2 eq of DIEA
[0030] Wherein A represents α-conotoxin of α9α10 acetylcholine receptor and its modified polypeptide derivatives, such as PeIA and its derivatives, RgIA and its derivatives RgIA4, Vc1.1 and its derivatives, GeXIVA and its derivatives, Gex-2 and its analogs, etc.
[0031] Wherein B represents a conjugate, and the conjugate can prevent proteases in plasma from degrading α-conotoxin and modified polypeptide derivatives of α-conotoxin.
[0032] Further, the conjugate is selected from fatty acids and polyethylene glycol, and further, the carbon number of the fatty acid is C 2-25 , preferably C 2-20 , more preferably the number of carbon atoms is C 10-20 , further preferably the fatty acid chain in Table 1; the molecular weight of the polyethylene glycol is not less than 1000, preferably 300-800, and further preferably the polyethylene glycol (PEG) in Table 2.
[0033] A and B are linked by a covalent bond, which is an amide bond or an ester bond.
[0034] The analgesic polypeptide of the present invention usually carries a positive charge and is very easy to bind to plasma proteins, resulting in polypeptide degradation. It can bind to serum albumin in plasma through conjugates such as fatty acid chains or polyethylene glycol, and by shielding the positive charge on the polypeptide, reduce the degradation of polypeptide derivatives by proteases and improve their plasma stability. The fatty acid chain of appropriate length or polyethylene glycol of appropriate molecular weight can greatly improve its stability in vivo while maintaining the activity of the polypeptide. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Figure 1 .Stability of Gex-2 and its derivatives in human serum. (A) Stability of Gex-2 and its fatty acid derivatives in human serum; (B) Stability of Gex-2 and its PEG derivatives in human serum.
[0036] Figure 2. Pain threshold test of Gex-2 analogs at a concentration of 25 μg / kg 1 hour after administration. (A) Effects of Gex-2 analogs coupled with polyethylene glycol on the mechanical pain threshold of CCI rats; (B) Effects of Gex-2 analogs coupled with fatty acid chains on the mechanical pain threshold of CCI rats.
[0037] Figure 3 . Pain threshold test of Gex-2 analogs at a concentration of 25 μg / kg 24 hours after administration. (A) Effects of Gex-2 analogs coupled with polyethylene glycol on mechanical pain threshold of CCI rats; (B) Effects of Gex-2 analogs coupled with fatty acid chains on thermal pain threshold of CCI rats.
[0038] Figure 4 .Weight of rats at the end of CCI experiment
[0039] Figure 5 .Toxicity of Gex-2 derivatives on HEK-293T cells. (A) Cytotoxicity of Gex-2 coupled with PEG6; (B) Cytotoxicity of Gex-2 coupled with PEG8; (C) Cytotoxicity of Gex-2 coupled with FA16; (D) Cytotoxicity of Gex-2 coupled with FA18. DETAILED DESCRIPTION
[0040] In order to better understand the present invention, some terms are first defined. Other definitions are listed throughout the detailed description. At the same time, the contents of CN202011382117.2 are all introduced into the present invention.
[0041] As used herein, the term "polypeptide" is intended to encompass a single "polypeptide" as well as a plurality of "polypeptides", and refers to a molecule composed of monomers (amino acids) linearly linked by amide bonds (also referred to as peptide bonds). The term "polypeptide" refers to any one or more chains containing two or more amino acids, and does not refer to a specific length of the product. Thus, peptides, dipeptides, tripeptides, oligopeptides, "proteins", "amino acid chains" or any other terms used to represent one or more chains of two or more amino acids are included in the definition of "polypeptide", and the term "polypeptide" may be used instead of or interchangeably with any of these terms.
[0042] The polypeptides of the invention or modified polypeptides may have a size of about 3 or more, 5 or more, 10 or more, 20 or more, 25 or more, 50 or more amino acids. Polypeptides may have a defined three-dimensional structure, but they do not have to have such a structure. Polypeptides with a defined three-dimensional structure are referred to as folded, and polypeptides that do not have a defined three-dimensional structure, but can adopt many different conformations, are referred to as unfolded.
[0043] The active polypeptide derived from conotoxin of the present invention can be extended or shortened according to the sequence of natural conotoxin. Cutting the sequence of conotoxin usually reduces its activity, but there are exceptions, such as the N-terminal free end of GID conotoxin (a free polypeptide fragment of 4 amino acids), which can still retain the activity of targeting α4β2nAChR after cutting (J Biol Chem. 2009 Feb 20; 284 (8): 4944-51). Therefore, it is possible to substantially retain the activity of the polypeptide by cutting 1-4 amino acids at the N-terminal.
[0044] The term "polypeptide" or modified "polypeptide" or polypeptide derivative is also intended to represent a post-expression modified product of the polypeptide, including but not limited to glycosylation, acetylation, phosphorylation, amidation, derivatization by known protection / blocking groups, proteolytic cleavage, or modification by non-natural amino acids. The polypeptide may be derived from a natural biological source or produced by recombinant technology, but need not be translated from a specified nucleic acid sequence. It may be produced in any manner, including by chemical synthesis. In the process of polypeptide structure optimization, non-natural modification or glycosylation strategies are generally used to improve the activity, stability and selectivity of the polypeptide. The stability of the polypeptide can be improved by replacing the natural amino acids in the sequence with non-natural amino acids of similar physicochemical properties (J Biol Chem. 2009Apr 3; 284(14): 9498-512.; ACS Chem Neurosci. 2019Oct 16; 10(10): 4328-4336). For example, replacing the basic amino acid Arg in the Gex-2 sequence with Arg-1 (an arginine analog with a side chain length of 4 C), Arg-2 (an arginine analog with a side chain length of 2 C), Arg-3 (an arginine analog with a side chain length of 1 C) can potentially retain or improve its activity.
[0045] 4-(R)-hydroxy-L-proline, [4-(R)-OH], 4-(R)-amino-L-proline, [4-(R)-NH2], 4-(S)-amino-L-proline, [4-(S)-NH2], 4-(R)-guan idino-L-proline,[4-(R)-Gn], 4-(R)-betainamidyl-L-proline,[4-(R)-Bet], 4-(R)-fluoro-L-proline,[4-(R)-F], 4-(S)-fluoro- L-proline,[4-(S)-F], 4-(R)-phenyl-L-proline,[4-(R)-Ph], 4-(S)-phenyl-L-proline,[4-(S)-Ph4-(R)-1-naphthylmethyl-L-pro line, 4-(R)-Nap]4-()-benzyl-L-proline,[4-(R)-Bzl3-(S)-phenyl-L-proline,[3-(S)-Ph], 5-(R)-phenyl-L-proline,[5-(R)-Ph]
[0046] The activity of Gex-2 can be potentially retained or even improved. The glycosylation method can significantly improve the stability, half-life and bioavailability of peptides (Trends Biochem. Sci. 2006, 31, 156-163; Carbohydr. Res. 2009, 344, 1508-1514; Front Pharmacol. 2013 Dec 13; 4: 155). Currently, the glycosylated amino acids mainly include Ser, Thr and Asn. Therefore, it can be expected that glycosylation of Ser or Thr at position 5 in the Gex-2 sequence can improve the stability, half-life and bioavailability of the peptide.
[0047] The polypeptide of the present invention also includes fragments, derivatives, analogs or variants of the aforementioned polypeptides and any combination thereof. When referring to the polypeptide of the present invention, the terms "fragment", "variant", "derivative" and "analog" include retaining at least some biological activities and / or functions of the corresponding polypeptide.
[0048] Variants of the polypeptides of the present invention include fragments of the polypeptides, and polypeptides having altered amino acid sequences due to amino acid substitutions, deletions or insertions. Variants may occur naturally or may occur non-naturally. Non-naturally occurring variants may be produced using mutagenesis techniques known in the art. Variant polypeptides may contain conservative or non-conservative amino acid substitutions, deletions or additions. A derivative of a polypeptide is a polypeptide that has been altered to exhibit additional features not found on a natural polypeptide. Examples include fusion proteins. Variant polypeptides may also be referred to herein as "polypeptide derivatives". As used herein, a "derivative" of a polypeptide refers to a subject polypeptide having one or more residues chemically derived by reaction of a functional side group. "Derivatives" also include those peptides containing one or more naturally occurring amino acid derivatives of the twenty standard amino acids. For example, 4-hydroxyproline may replace proline; 5-hydroxylysine may replace lysine; 3-methylhistidine may replace histidine; homoserine may replace serine; and ornithine may replace lysine. The amino acids used in the present invention may be D- or L-isomers or mixtures thereof.
[0049] The term "composition" or "pharmaceutical composition" may include a composition containing an active polypeptide of the present invention and, for example, a pharmaceutically acceptable carrier, excipient or diluent, which is administered to a subject.
[0050] The term "pharmaceutically acceptable" refers to compositions that are suitable for contact with the tissues of humans and animals without excessive toxicity or other complications, commensurate with a reasonable benefit / risk ratio, within the scope of sound medical judgment. In some aspects, the polypeptides, polynucleotides, compositions and vaccines described herein are pharmaceutically acceptable.
[0051] The term "subject" refers to any subject, particularly a mammalian subject, for whom diagnosis, prognosis, immunization or treatment is desired. Mammalian subjects include, but are not limited to, humans, domestic animals, farm animals, zoo animals such as bears, sports animals, pet animals such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, bears, cows; primates such as apes, monkeys, gorillas and chimpanzees; canines such as dogs and wolves; felines such as cats, lions and tigers; equines such as horses, donkeys and zebras; food animals such as cattle, pigs and sheep; ungulates such as deer and giraffes; rodents such as mice, rats, hamsters and guinea pigs, etc. In a preferred embodiment, the subject is a human.
[0052] Example 1: Synthesis of Gex-2 linear polypeptide
[0053] The Fmoc solid phase synthesis method is used to synthesize the Gex-2 linear polypeptide, including the following steps:
[0054] 1. RAM resin was selected as the starting resin carrier (degree of substitution 0.324), and Fmoc removal was performed after DCM swelling for 30 minutes, with a removal time of 20 minutes and a temperature of 30°C;
[0055] 2. Wash the resin with DMF 5-6 times and then with DCM;
[0056] 3. Weigh 3eq of the first amino acid at the C-terminus of the resin and 3eq of HBTU, add them to the resin reaction bottle, add DMF to bubble the resin, then add 6eq of DIEA, and react at 30°C for 30 min;
[0057] 4. Wash the resin with DMF 5-6 times and then with DCM;
[0058] 5. Weigh 3eq of the second amino acid at the C-terminus of the resin and 3eq of HBTU, add them to the resin reaction bottle, add DMF to bubble the resin, then add 6eq of DIEA, and react at 30℃ for 30min;
[0059] 6. Repeat step 5 until the linear peptide is synthesized.
[0060] Example 2: Synthesis of Gex-2-PEG
[0061] PEG4, PEG6 and PEG8 are selected as PEG. The preparation method is given by taking PEG4 as an example, and the preparation methods of PEG6 and PEG8 are the same as described below.
[0062] PEG4:
[0063] Fmoc-NH-PEG4-CH2COOH is an oily light yellow liquid. Weigh 1.5eq of resin, select 2eq of Pybop as condensing agent, and select 2eq of DIEA as organic base. React at room temperature for 4h. After the reaction is completed, use trifluoroacetic acid / water / ethanedithiol / phenol / thioanisole = 90:5:2.5:7.5:5 to cut the polypeptide from the resin, and use ice ether precipitation and washing to recover the crude linear peptide. The molecular weight is identified by mass spectrometry, and the polypeptide sample is purified by preparative reverse HPLC C8 column. Solvent A is 90% pure water, 10% acetonitrile (ACN) and 0.1% trifluoroacetic acid (TFA); Solvent B is 60% pure water, 40% acetonitrile (ACN) and 0.1% trifluoroacetic acid (TFA), and the elution linear gradient is to make solvent B from 0% to 60% within 40min. After purification, use analytical HPCC18 column for purity detection to ensure that its purity reaches more than 96%.
[0064] Example 3: Synthesis of Gex-2-FA
[0065] Exemplary fatty acids include FA16, FA17 and FA18
[0066] Weigh out 1.2-1.5eq of fatty acid from the resin, select 2eq of Pybop as the condensing agent, and 2eq of DIEA as the organic base, and react at room temperature for 4 hours. After the reaction is completed, use mass spectrometry to identify the molecular weight, and then purify. After purification, use an analytical HPCC18 column for purity detection to ensure that its purity reaches more than 96%.
[0067] Example 4: Stability Evaluation
[0068] Experimental methods
[0069] 1. Human serum was centrifuged at 15000g for 15 min to remove lipids, and then incubated at 37°C for 15 min to gradually restore the enzyme activity in the serum to the optimal level;
[0070] 2. Dissolve the polypeptides obtained in Examples 2 and 3 in physiological saline to prepare a polypeptide solution with a final concentration of 0.25 mM at a ratio of polypeptide: serum = 1:9;
[0071] 3. Incubate the peptide serum solution at 37°C, take out three equal portions at 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 h, 30 μL each, add 30 μL 20% TFA and cold extract at 4°C for 10 min;
[0072] 4. Centrifuge at 14000 g for 10 min, take the supernatant, and analyze by RP-UPLC at a rate of 0.5 mL / min using a linear gradient of Buffer B (90% acetonitrile plus 0.1% TFA) using a Phenomenex C18 analytical column and detect at 214 nm.
[0073] Example 5: Stability Evaluation
[0074] stability
[0075] We used Gex-2 as a control and tested the stability of fatty acid derivatives and PEG derivatives in human serum. The test results are as follows: Figure 1 As shown, Figure 1 .Stability of Gex-2 and its derivatives in human serum. (A) Stability of Gex-2 and its fatty acid derivatives in human serum; (B) Stability of Gex-2 and its PEG derivatives in human serum. Figure 1 It can be seen that Gex-2 has poor stability in human serum and is almost completely degraded after 1 hour. However, when fatty acid chains or PEG are coupled to Gex-2, the stability of Gex-2 is greatly improved, and its fatty acid and PEG derivatives are almost not degraded within 24 hours, indicating that we have successfully improved the serum stability of Gex-2 by fatty acid / PEG coupling.
[0076] In vivo activity
[0077] We established a rat sciatic nerve chronic constriction injury (CCI) model and tested the analgesic activity of Gex-2 derivatives Gex-2-PEG6, Gex-2-PEG8, Gex-2-FA16, and Gex-2-FA18 in CCI rats.
[0078] First, we tested the analgesic activity of 25 μg / kg of the derivative in CCI rats. The positive control was pregabalin, a drug used to treat neuropathic pain on the market. The drug was administered continuously for one week, and the mechanical pain paw withdrawal threshold (PWT) of the rats was measured at 1h and 24h after each administration.
[0079] Table 1. Animal group-level drug administration experimental design
[0080]
[0081]
[0082] The pain threshold of rats tested 1 hour after administration was Figure 2 As shown:
[0083] Figure 2 .Pain threshold test of Gex-2 analogs at a concentration of 25μg / kg 1 hour after administration. (A) Effect of Gex-2 analogs coupled with polyethylene glycol on the mechanical pain threshold of CCI rats; (B) Effect of Gex-2 analogs coupled with fatty acid chains on the mechanical pain threshold of CCI rats. As can be seen from the figure, from the mechanical pain data, the analgesic effect of the derivatives of Gex-2 coupled with 6 polyethylene glycol is not obvious, while the derivatives of Gex-2 coupled with 8 polyethylene glycol and the fatty acid derivatives of Gex-2 have a significant effect on alleviating the pain of CCI rats, and the analgesic effect is equivalent to that of 30mg / kg of pregabalin. The data show that for the relief of acute pain, the order of the four derivatives should be PEG8>FA16≈FA18>PEG6. The pain threshold of rats tested 24 hours after administration is as follows Figure 3 As shown: Figure 3 . Pain threshold test of Gex-2 analogs at a concentration of 25 μg / kg 24 hours after administration. (A) Effect of Gex-2 analogs coupled with polyethylene glycol on mechanical pain threshold of CCI rats; (B) Effect of Gex-2 analogs coupled with fatty acid chains on thermal pain threshold of CCI rats. Figure 3As shown in the figure, 24 hours after administration, Gex-2 derivatives still have certain analgesic activity, but at this time the activity of the fatty acid derivative series is higher than that of the polyethylene glycol derivative series. This is because the binding between the fatty acid chain and serum albumin is equivalent to a sustained release of Gex-2, so the FA derivatives can exert their efficacy longer than the PEG derivatives.
[0084] On the day the experiment was completed, we weighed the rats in different groups and recorded the results. Figure 4 As shown: According to the observation of the diet of rats, it was found that the diet of the drug-treated group did not change significantly, and as shown in Figure 4 As shown, continuous administration did not affect the weight of rats. Through observation of rats, we found that the hair gloss of rats in all groups was normal, and the food and water intake of rats in different groups was basically the same. Rats did not experience gastrointestinal reactions, and no neurotoxic side effects such as depression were observed.
[0085] Cytotoxicity
[0086] In terms of plasma stability and in vivo analgesic activity, there was no significant difference between the polyethylene glycol derivatives and fatty acid chain derivatives of Gex-2, so we conducted cytotoxicity tests on the two types of derivatives, hoping to select the most suitable conjugation method for Gex-2 through comprehensive activity and safety evaluation results.
[0087] We used HEK-293T human embryonic kidney cells to test the cytotoxicity of four Gex-2 derivatives. Figure 5 As shown:
[0088] Figure 5 .Toxicity of Gex-2 derivatives on HEK-293T cells. (A) Cytotoxicity of Gex-2 coupled with PEG6; (B) Cytotoxicity of Gex-2 coupled with PEG8; (C) Cytotoxicity of Gex-2 coupled with FA16; (D) Cytotoxicity of Gex-2 coupled with FA18.
[0089] Depend on Figure 5 It can be seen that the polyethylene glycol derivative of Gex-2 is relatively safe and will not cause damage or death to HEK-293T cells at a concentration of 50 μM, which is much higher than the administered dose. The fatty acid chain derivatives show cytotoxicity at a concentration of 1 μM, with the cell survival rate of Gex-2-FA16 being less than 70% at a concentration of 50 μM and the cell survival rate of Gex-2-FA18 being only 20% at a concentration of 50 μM, indicating that Gex-2 will produce strong cytotoxicity after coupling with fatty acid chains.
[0090] Based on the stability, activity, and cytotoxicity data of both polyethylene glycol and fatty acid chain derivatives, we believe that both polyethylene glycol and fatty acid conjugation are suitable modification methods for Gex-2.
Claims
1. An application of an analgesic polypeptide in the preparation of a drug for chronic pain diseases, wherein the analgesic polypeptide has a structure of AB, wherein A is selected from Gex 2, wherein B represents a conjugate, and the conjugate can prevent proteases in plasma from degrading α-conotoxin and α-conotoxin modified polypeptide derivatives, A and B are linked by a covalent bond, wherein the conjugate comprises polyethylene glycol and a fatty acid, wherein the polyethylene glycol is selected from PEG8; and the fatty acid is selected from palmitic acid.
2. An analgesic pharmaceutical composition, comprising an analgesic polypeptide and optional pharmaceutically acceptable excipients, characterized in that: The structure of the analgesic polypeptide is AB, wherein A is selected from Gex 2, wherein B represents a conjugate, and the conjugate can prevent proteases in plasma from degrading α-conotoxin and modified polypeptide derivatives of α-conotoxin, and A and B are linked by covalent bonds, wherein the conjugate is polyethylene glycol and fatty acid, the polyethylene glycol is PEG8; and the fatty acid is palmitic acid.
Citation Information
Patent Citations
Modifications and uses of conotoxin peptides
CN107249616A
Alpha9alpha10nAChR inhibitory active peptide and application thereof
CN114573674A
